- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: BMS-650032 | BMS650032 | compound 24 [PMID: 24564672] | Sunvepra™
asunaprevir is an approved drug (Japan (2014), Canada (2016))
Compound class: Synthetic organic
Comment: Asunaprevir (BMS-650032) is an orally bioavailable, oligopeptide-based inhibitor of the nonstructural protein 3 (NS3), from hepatitis C virus (HCV) . NS3, is a serine protease that is essential for proteolytic cleavages within the HCV polyprotein, a function that is key during HCV viral RNA replication. More recently asunaprevir has been reported to inhibit the papain-like protease (PL-pro, nsp3) in a number of coronaviruses .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Akamatsu N, Sugawara Y, Kokudo N. (2015)
Asunaprevir (BMS-650032) for the treatment of hepatitis C virus.
Expert Rev Anti Infect Ther, 13 (11): 1307-17. [PMID:26414905]
2. Anson BJ, Chapman ME, Lendy EK, Pshenychnyi S, D’Aquila RT, Satchell KJF, Mesecar AD. (2020)
Broad-spectrum inhibition of coronavirus main and papain-like proteases by HCV drugs.
Nature Research, PrePrint, Under Review. DOI: 10.21203/rs.3.rs-26344/v1
3. Bristol Myers Squibb.
Bristol-Myers Squibb Statement about Asunaprevir in the U.S.
Accessed on 19/05/2020. Modified on 19/05/2020. news.bms.com, https://news.bms.com/press-release/rd-news/bristol-myers-squibb-statement-about-asunaprevir-us
4. Scola PM, Sun LQ, Wang AX, Chen J, Sin N, Venables BL, Sit SY, Chen Y, Cocuzza A, Bilder DM et al.. (2014)
The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection.
J Med Chem, 57 (5): 1730-52. [PMID:24564672]